Skip to main content

Table 1 Comparative analysis of full-field electroretinography (ERG) responses

From: Preclinical assessment of intravitreal ramucirumab: in vitro and in vivo safety profile

 

Rods

Combined A

Combined B

Cone A

Cone B

Flicker

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

C1–C4

 OD

83.1 (54.0–119.0)

155.5 (103.0–162.0)

0.0679

42.5 (36.7–70.5)

52.3 (44.7–61.9)

0.4652

146.0 (84.3–165.0)

202.5 (119.0–241.0)

0.0679

10.1 (6.2–15.3)

9.5 (7.8–12.8)

0.4652

105.0 (61.7–115.0)

94.8 (63.7–118.0)

0.9999

66.0 (48.3–77.8)

76.5 (42.3–94.1)

0.4652

 OS

69.8 (34.2–134.0)

185.5 (153.0–251.0)

0.0679

36.5 (23.4–71.7)

72.3 (45.1–80.5)

0.0679

135.0 (80.4–163.0)

227.5 (188.0–301.0)

0.0679

8.6 (6.3–11.7)

8.9 (5.4–17.4)

0.4652

97.7 (60.5–111.0)

102.3 (70.1–176.0)

0.0679

54.1 (32.1–75.2)

95.1 (64.7–115.0)

0.0679

C5–C8

 OD

108.2 (16.9–160.0)

154.5 (135.0–205.0)

0.0679

50.8 (10.5–62.8)

62.0 (60.1–64.9)

0.0679

146.0 (27.8–181.0)

178.0 (151.0–205.0)

0.0679

7.2 (1.8–10.6)

10.4 (7.9–13.6)

0.0679

63.8 (12.7–86.3)

99.7 (65.8–127.0)

0.1441

66.7 (6.24–81.0)

79.3 (72.1–104.0)

0.0679

 OS

115.7 (51.6–207.0)

142.5 (84.0–188.0)

0.5807

53.1 (28.4–87.1)

61.7 (40.3–69.8)

0.715

148.0 (79.2–236.0)

179.0 (118.0–217.0)

0.4652

8.5 (5.9–11.0)

9.3 (7.2–13.4)

0.2733

69.6 (53.7–100.0)

74.1 (71.4–129.0)

0.1441

67.5 (25.7–110.0)

61.9 (50.5–82.2)

0.715

C9–C11

 OD

101.0 (37.3–104.0)

101.0 (93.5–156.0)

0.285

44.7 (40.2–60.3)

58.7 (39.7–68.8)

0.9999

134.0 (57.8–160.0)

169.0 (147.0–234.0)

0.1088

9.1 (7.5–9.5)

10.1 (8.9–11.9)

0.1088

86.2 (63.9–99.8)

108.0 (90.9–132.0)

0.1088

61.9 (42.7–72.0)

63.5 (58.4–69.0)

0.593

 OS

117.0 (26.9–119.0)

133.0 (96.7–179.0)

0.1088

46.7 (35.5–51.4)

63.2 (33.3–82.3)

0.285

113.0 (54.7–169.0)

208.0 (125.0–238.0)

0.1088

11.3 (5.7–11.8)

11.6 (11.2–14.8)

0.285

85.7 (52.1–110.0)

91.6 (79.7–107.0)

0.285

56.6 (34.0–89.1)

88.4 (68.8–89.6)

0.1088

C12–C16

 OD

105.0 (93.3–163.0)

113.0 (94.7–170.0)

0.9999

57.7 (49.2–62.7)

42.1 (37.5–50.3)

0.285

143.0 (133.0–154.0)

127.0 (126.0–173.0)

0.9999

7.4 (7.0–7.6)

8.1 (4.5–8.3)

0.9999

74.1 (60.5–86.2)

52.7 (48.4–89.7)

0.285

50.9 (49.4–71.7)

51.6 (33.4–71.7)

0.9999

 OS

114.0 (99.5–175.0)

108.0 (108.0–110.0)

0.593

58.6 (55.6–69.1)

43.3 (34.9–46.8)

0.1088

165.0 (134.0–177.0)

131.0 (128.0–132.0)

0.1088

8.6 (8.4–11.1)

6.7 (5.0–7.1)

0.1088

95.7 (65.7–99.6)

59.0 (51.2–75.3)

0.1088

71.6 (57.6–84.0)

48.6 (45.0–56.5)

0.1088

  1. Full-field ERG amplitude in rabbits injected with ramucirumab in the right eye (OD) or BSS in the left eye (OS). Values of amplitude presented as median (range). Statistical analysis was performed using Wilcoxon signed-rank test. C1–C4 (500 µg group with 24 h of follow-up); C5–C8 (500 µg group with 7 days of follow-up); C9–C11 (250 µg group with 24 h of follow-up); C12–C16 (250 µg group with 7 days of follow-up)